Self‐administered non‐invasive vagus nerve stimulation therapy for severe pharmacoresistant restless legs syndrome: outcomes at 6 months

Sarah Hartley, Guillaume Bao, Ashley Russo, Marine Zagdoun, Sylvain Chevallier, Frédéric Lofaso, Antoine Léotard, Éric AzabouJournal of Sleep Research 2023 · DOI

TL;DR

This study explores the effectiveness of self-administered transauricular vagus nerve stimulation (taVNS) for severe, treatment-resistant Restless Legs Syndrome (RLS). The findings suggest that weekly home-based taVNS can significantly reduce RLS symptom severity, improve quality of life, and alleviate anxiety and depression symptoms over a 6-month period, offering a promising new therapeutic avenue for patients with limited treatment options.

What Problem Does This Paper Address?

Restless Legs Syndrome (RLS) is a common neurological disorder characterized by an irresistible urge to move the legs, often accompanied by uncomfortable sensations. While various treatments exist, a significant portion of patients develop "pharmacoresistant" RLS, meaning they do not respond adequately to conventional therapies or experience problematic side effects like augmentation (worsening of symptoms over time). This leaves a substantial group of individuals suffering from severe RLS with limited management options, leading to a reduced quality of life and increased risk of mood disorders. The paper addresses the urgent need for innovative and effective treatments for this challenging patient population.

Methods

The study employed a case series design, building upon an initial 8-week hospital-based transauricular vagus nerve stimulation (taVNS) protocol. Following the hospital phase, 15 patients with severe pharmacoresistant RLS were offered self-administration of taVNS at home, using portable stimulators and individualised settings. Patients were trained to perform weekly 1-hour sessions. The primary outcome measure was the change in the International Restless Legs Rating Scale (IRLS) score, which quantifies RLS symptom severity. Secondary outcome measures included quality of life (assessed by the RLSQOL questionnaire) and mood disorders (using the Hospital Anxiety and Depression Scale - HADS). Data was collected at baseline, after the initial hospital sessions, and at the 6-month follow-up. Statistical analysis involved non-parametric tests for paired data.

Datasets

Not discussed in the paper.

Key Insights and Ideas

  • Feasibility of Self-Administration: The study demonstrates that patients can successfully be trained to self-administer taVNS at home, making the treatment more accessible and sustainable for long-term management.
  • Sustained Efficacy: While initial improvements were observed during the hospital-based phase, the 6-month follow-up indicates that weekly self-administered taVNS can maintain and even further improve RLS symptom severity.
  • Beyond Symptom Reduction: The positive impact of taVNS extends beyond just RLS symptoms, showing significant improvements in quality of life and reductions in anxiety and depression, which are common comorbidities.
  • Potential for Augmentation Syndrome: The paper speculates that taVNS might play a role in managing or preventing augmentation syndrome, a significant challenge in RLS treatment, though further research is needed.
  • Individual Variability: The study highlights that patients respond differently to taVNS, with some showing continuous improvement, others stability, and some experiencing a gradual return of symptoms, suggesting a need for personalized treatment approaches.

Key Results

  • Symptom Severity: At 6 months, the mean IRLS score decreased significantly from a baseline of 31.9 to 22.2 (p = 0.0005). Four out of 15 patients achieved an IRLS score below 20 (considered severe RLS), with two patients reaching a score of 5. No patient experienced worsening of symptoms.
  • Quality of Life: The RLSQOL score significantly improved from a baseline of 49.3 to 65.66 at 6 months (p = 0.0005).
  • Mood Disorders: Anxiety symptoms (HADA score) decreased from a baseline of 8.9 to 7.53 at 6 months (p = 0.029), and depression symptoms (HADD score) decreased from 5.2 to 4.73 (p = 0.03).
  • Tolerability: The taVNS treatment was well-tolerated, with no adverse events reported during the 6-month follow-up.
  • Adherence: 13 out of 15 patients continued weekly taVNS at home for the 6-month duration.

Limitations and Future Work

The authors acknowledge several limitations:

  • Small Sample Size and Case Series Design: The study is a small, non-randomized pilot study. Without a randomized controlled design, it's difficult to definitively attribute the observed improvements solely to taVNS.
  • Lack of Polysomnography (PSG): The absence of baseline PSG means underlying obstructive sleep apnea (OSA), which can complicate RLS management, could not be excluded. The impact of taVNS on sleep-related breathing disorders also remains unknown.
  • No Objective Adherence Data: While patients self-reported adherence, there were no objective measures to confirm consistent and correct use of the device at home.
  • Potential for Reduced Efficacy at Home: Some patients reported initial difficulties with electrode placement and stability at home, which might have potentially reduced stimulation efficacy compared to the hospital setting.
  • Uncertainty about Optimal Parameters: Key parameters for taVNS in RLS, such as optimal frequency, session duration, and timing, remain undefined.

Future Work: The authors strongly advocate for randomized controlled trials (RCTs) to confirm the efficacy and safety of taVNS for severe pharmacoresistant RLS. Future research should also focus on defining optimal treatment parameters, investigating the long-term effects beyond 6 months, and exploring the potential role of taVNS in managing augmentation syndrome. Further studies could also incorporate objective sleep monitoring (PSG) and explore biomarkers for taVNS effectiveness.

Summary updated

Abstract

Severe pharmacoresistant restless legs syndrome (RLS) is difficult to manage and a source of suffering to patients. We studied the effectiveness at 6 months of an innovative treatment: transauricular vagus nerve stimulation (taVNS) in the left cymba concha in a case series of 15 patients, 53% male, mean (SD) age 62.7 (12.3) years with severe pharmacoresistant RLS (mean [SD] International Restless Legs Rating Scale [IRLS] score of 31.9 [2.9]) at baseline. Following an 8-week non-randomised hospital-based study with eight 1-h sessions of taVNS, patients were trained to administer taVNS at home and were followed up for 6 months. The primary outcome measure was the IRLS score, secondary outcome measures were quality of life, mood disorders using the Hospital Anxiety and Depression scale (HAD) subscales for depression (HADD) and anxiety (HADA). At the 6-month follow-up 13/15 patients continued to use weekly taVNS. Symptom severity decreased (mean [SD] IRLS score 22.2 [9.32] at 6 months, p = 0.0005). Four of the 15 patients had an IRLS score of <20 at 6 months and two an IRLS score of 5. Quality of life significantly improved compared to baseline (mean [SD] score at baseline 49.3 [18.1] versus 65.66 [22.58] at 6 months, p = 0.0005) as did anxiety and depression symptoms (mean [SD] HADA score at baseline 8.9 [5.4] versus 7.53 [4.42] at 6 months, p = 0.029; and HADD score at baseline 5.2 [4.5] versus 4.73 [4.44] at 6 months, p = 0.03). Treatment was well tolerated, and no adverse events were reported. Our case series shows a potential role for self-administered taVNS in patients with severe pharmacoresistant RLS. Randomised controlled trials are needed to confirm the utility of taVNS.
BibTeX
@article{hartley2023selfadministered,
  author = {Sarah Hartley and Guillaume Bao and Ashley Russo and Marine Zagdoun and Sylvain Chevallier and Frédéric Lofaso and Antoine Léotard and Éric Azabou},
  title = {{Self‐administered non‐invasive vagus nerve stimulation therapy for severe pharmacoresistant restless legs syndrome: outcomes at 6 months}},
  journal = {Journal of Sleep Research},
  year = {2023},
  doi = {10.1111/jsr.14066},
}

Loading related content...

Figure